

**Errata – FDA Clinical Briefing Document**  
**PDAC February 6, 2008**  
**Olanzapine Pamoate Depot (Eli Lilly and Company)**

1. Page 6, under 3.2 Animal Pharmacology/Toxicology, replace only sentence with:

“Data from non-Clinical toxicology and ADME (absorption, distribution, metabolism and elimination) studies were provided with the submission. Please refer to the pharmacology/toxicology review for detailed pharmacology and toxicology information.”

2. Page 8 &9, under 5.1, 5.2, 5.3 replace the statement

“Please refer to his review for pertinent information.”

with the following statement:

“At the time of completion of this review, Dr. Jackson’s review is pending.”

3. Page 40, under the subtitle of *the Possible Cause of the Excessive Sedation Events*, replace the date in the first sentence of the 2<sup>nd</sup> paragraph with July 2006
4. Page 42, the last sentence of the second paragraph should be deleted.
5. Page 48, section 7.2.6, Adequacy of Metabolic, Clearance and Interaction Workup. Replace the single sentence in this section with: “A detailed review of metabolism, clearance, and interaction workup will be found in Dr. Andre Jackson’s review, which is pending.”
6. Front cover page, replace “Dosing Regimen 210 mg/3 ml, 300 mg/3 ml, and 405 mg/3 ml” with “Dosing Regimen 300 mg/2 weeks, 405 mg/4 weeks, 210 mg/ 2 weeks, 150 mg/ 2 weeks”